Zühlke Group’s Post

The Boston University CTE Center is pushing the boundaries of neurodegenerative research, led by renowned experts Dr. Ann McKee, Dr. Thor Stein, and Dr. Michael L. Alosco at the Boston University School of Medicine. Their groundbreaking work is shifting the paradigm for diagnosing chronic traumatic encephalopathy (CTE), a condition linked to memory loss, confusion, and aggression, which currently can only be confirmed postmortem. Through the Bank CTE study, Boston University researchers are advancing closer to identifying #CTE in living individuals, potentially revolutionizing treatment options and prevention strategies. By following 1,000 participants with a history of contact sports or military service, BU aims to find biomarkers—traces of CTE in blood or brain scans—that could one day lead to early diagnosis and intervention. This cutting-edge research, combined with AI and machine learning, could make CTE a treatable disease, providing answers to patients and families long before it’s too late. Learn more ⬇️

Reisa Sperling, MD, Chris Van Dyck, MD, Dennis Selkoe, MD, and Larisa Reyderman, PhD, will be sharing our latest Alzheimer’s disease (AD) clinical data in Hall A today at #AAIC24 at 4:15 PM ET. Join us to hear the latest updates. #AlzheimersDisease #EndAlz

Alzheimer's disease is a growing global challenge, affecting over 55 million people worldwide. As the number of cases increases, the need for innovative research methods and early detection tools has never been more urgent. GRIP (Global Research & Imaging Platform) is leading the way in Alzheimer’s research, tackling the significant challenges in early detection and treatment of this devastating disease. They partnered with Zühlke Group to reduce barriers to data access, foster collaboration and ultimately accelerate research into Alzheimer’s disease, without compromising sensitive patient information. I'm very proud to be part of such an innovative and pioneering company 👏 Read more about the case study: https://lnkd.in/ddi25-Sk

Coming Soon: CNSA's next white paper on Alzheimer's disease. Panelists will discuss the burden of Alzheimer's disease, the value of timely diagnosis, access to treatment and use of new diagnostic tools. Learn more ▶️ https://bit.ly/3a2xoEh

Coming Soon: CNSA's next white paper on Alzheimer's Disease. Panelists will discuss the burden of Alzheimer's disease, the value of timely diagnosis, access to treatment and use of new diagnostic tools. Learn more ▶️ https://bit.ly/3a2xoEh

The University of Kansas Alzheimer’s Disease Research Center has entered into a collaboration with Brigham Young University to conduct a validation study of a blood test for the early detection of neurodegeneration in Alzheimer’s disease. If successful, in addition to aiding in the early detection of Alzheimer’s, this test could assist in the monitoring of disease progression and help develop new diagnostic tools and treatments. Learn More: https://ow.ly/lcZj50Ux4rw #AlzheimersResearch #HopeForACure #BYU #UtahLifeSciences #LifeSciences #KansasUniversity

In an effort to streamline the drug-screening process, pre-formed fibril-induced reproducible models of #Alzheimer's & #Parkinson's disease were developed in a research study funded by InnoSer - On the Blog 👓 https://bit.ly/3Uje6hb

Day 11 of #100DaysofAI 🧪 (project catchup) Today I learned how to scrape data from any website using @BrowseAI. The tutorial was based on apartment rentals in Seattle, but to make it more practical for my likely needs I ran a scrape on recent publications on semaglutide and Alzheimer's disease. Here's a sample of what I extracted

Great articles from our colleagues in DTI, Dementia Trials Ireland. 👇 The prevalence and consequence of various forms of #dementia, inc. #Alzheimer's disease, is growing in Ireland and globally. However, new biomedical insight is helping drive enormous diagnostic and treatment opportunities where #clinicaltrials and #research is, and will, open up better pathways for diagnosis, management and outcome improvement; giving hope to those impacted and driving further improvements in care. The national network of DTI, Dementia Trials Ireland provides a great opportunity for Ireland to play a leading role in informing and driving advances in this rapidly evolving field. 👏

🧫 In vitro #NeurodegenerativeDisease assays prove to be both cost and time-effective, as they provide both target-specific insights and offer relatively higher throughput capabilities compared to in vivo models. In an effort to support neurodegenerative disease research, the neurology expert team led by Jolien B. at InnoSer has characterised and validated multiple in vitro assays using pre-formed fibrils supplied by StressMarq Biosciences Inc.. 👉 To continue reading more about our in vitro neurodegenerative diseases such as Parkinson's and Alzheimer's disease, read StressMarq Biosciences Inc.'s blogpost. Alternatively, head down to the InnoSer webpage to learn more about the use of these assays in drug development: https://lnkd.in/gSzHcNAp #InVitroAssaysCRO #PreclinicalNeurologyCRO #PreclinicalResearchCRO